Humanigen Inc. (HGEN) Prices 8M Share Common Offering at $8.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiative
- CAE agrees to sell Flightscape unit to SITA for $500 million
- Stocks, bonds edge up ahead of 'formidable' week for risk
Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN”
September 17, 2020 9:14 PM EDTBURLINGAME, CA / ACCESSWIRE / September 17, 2020 / Humanigen, Inc. ("Humanigen") (OTCQB: HGEND)(NASDAQ: HGEN), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm' with its lead drug candidate lenzilumab, announced today that it has priced its underwritten public offering of 8,000,000 shares of common stock at a public offering price of $8.50 per share, resulting in gross proceeds to Humanigen of approximately $68 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about... More



